HYPOTHESIS: Interruption of the excitotoxic and inflammatory pathways implicated in endolymphatic @entity4 (ELH)-associated @entity393 ( @entity393 ) should afford hearing protection at the neuronal level. BACKGROUND: Previous work in our laboratory in the @entity19 model of ELH shows that @entity3733 ( @entity3733 ), an anti-inflammatory solvent, can slow the progression of @entity528 occurs. @entity10891 , a @entity2227 release inhibitor, may provide synergistic benefit. This study was designed to quantify the effects of @entity3733 and @entity10891 in a long-term model. METHODS: @entity840 with surgically induced ELH were sorted into 3 groups: @entity10891 + @entity3733 (Group 1), @entity3733 alone (Group 2), and untreated controls (Group 3). Animals in Groups 1 and 2 received daily injections of the study drug(s). All animals underwent auditory-evoked brainstem response evaluation every 4 weeks until 24 weeks, when they were sacrificed. Cochleae were preserved; spiral ganglion density was quantified. Animals without @entity4 were excluded from the study as surgical failures. RESULTS: Animals from all groups developed unilateral @entity393 . At the end of the experiment, @entity393 was significantly lower in Group 1 relative to Group 3 (p = 0.049) and trended toward lower in Group 2 relative to Group 3 (p = 0.097). Groups 1 and 2 were not different (p = 0.311). At the cellular level, there is no evidence of @entity528 in either treated group, whereas there is a significant @entity528 in the untreated group. CONCLUSION: These results confirm the hearing protection observed with @entity3733 in short-term studies. However, unlike the previous study, which showed no additive benefit to @entity10891 , the combined treatment group in this study showed a hearing-protective effect at 24 weeks. This indicates a potential additive benefit conferred by @entity10891 toward long-term hearing protection. The study also finds evidence of statistically significant neuronal protection with both treatment groups. Overall, study provides additional evidence that @entity3733 and @entity10891 may preserve or slow the long-term progression of ELH-associated @entity393 .

Hearing preservation in XXXX with long-standing endolymphatic @entity4 .

@entity2227 :: ('CHEBI:29987', 'Chemical') :: ['glutamate'] @entity19 :: ('10090', 'Species') :: ['mouse'] @entity4 :: ('MESH:D004487', 'Disease') :: ['hydrops'] @entity840 :: ('10141', 'Species') :: ['Guinea pigs'] @entity10891 :: ('MESH:D019782', 'Chemical') :: ['Riluzole', 'riluzole'] @entity3733 :: ('MESH:D004121', 'Chemical') :: ['dimethyl sulfoxide', 'DMSO'] @entity393 :: ('MESH:D034381', 'Disease') :: ['HL', 'hearing loss'] @entity528 :: ('MESH:D009410', 'Disease') :: ['HL before neuronal degeneration', 'neuronal degeneration']
@entity840 :: (10141,Species) :: ['Guinea pigs']
